Randomized phase II study of platinum-based chemotherapy plus controlled diet with or without metformin in patients with advanced non-small cell lung cancer.

[1]  Qi Wang,et al.  Hexokinase 2 Depletion Confers Sensitization to Metformin and Inhibits Glycolysis in Lung Squamous Cell Carcinoma , 2020, Frontiers in Oncology.

[2]  R. Rosell,et al.  Effect of Metformin Plus Tyrosine Kinase Inhibitors Compared With Tyrosine Kinase Inhibitors Alone in Patients With Epidermal Growth Factor Receptor-Mutated Lung Adenocarcinoma: A Phase 2 Randomized Clinical Trial. , 2019, JAMA oncology.

[3]  Chance M. Nowak,et al.  p63 and SOX2 Dictate Glucose Reliance and Metabolic Vulnerabilities in Squamous Cell Carcinomas. , 2019, Cell reports.

[4]  A. George,et al.  Molecular Mechanisms of p63-Mediated Squamous Cancer Pathogenesis , 2019, International journal of molecular sciences.

[5]  Han Sung Kang,et al.  Predicting Response to Neoadjuvant Chemotherapy in Patients With Breast Cancer: Combined Statistical Modeling Using Clinicopathological Factors and FDG PET/CT Texture Parameters , 2019, Clinical nuclear medicine.

[6]  O. Nanni,et al.  Metformin plus chemotherapy versus chemotherapy alone in the first-line treatment of HER2-negative metastatic breast cancer. The MYME randomized, phase 2 clinical trial , 2018, Breast Cancer Research and Treatment.

[7]  A. Jemal,et al.  Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries , 2018, CA: a cancer journal for clinicians.

[8]  Young Seol Kim,et al.  Metformin reduces the risk of cancer in patients with type 2 diabetes , 2018, Medicine.

[9]  R. Hamanaka,et al.  PFKFB3, a Direct Target of p63, Is Required for Proliferation and Inhibits Differentiation in Epidermal Keratinocytes. , 2017, The Journal of investigative dermatology.

[10]  Z. Xuan,et al.  The distinct metabolic phenotype of lung squamous cell carcinoma defines selective vulnerability to glycolytic inhibition , 2017, Nature Communications.

[11]  Z. Xiao,et al.  Metformin Promotes AMP-activated Protein Kinase-independent Suppression of ΔNp63α Protein Expression and Inhibits Cancer Cell Viability* , 2017, The Journal of Biological Chemistry.

[12]  Su Jin Lee,et al.  Differential expression and prognostic significance of GLUT1 according to histologic type of non-small-cell lung cancer and its association with volume-dependent parameters. , 2017, Lung cancer.

[13]  Eun Ho Kim,et al.  Metformin Radiosensitizes p53-Deficient Colorectal Cancer Cells through Induction of G2/M Arrest and Inhibition of DNA Repair Proteins , 2015, PloS one.

[14]  M. Reni,et al.  (Ir)relevance of Metformin Treatment in Patients with Metastatic Pancreatic Cancer: An Open-Label, Randomized Phase II Trial , 2015, Clinical Cancer Research.

[15]  G. Cheng,et al.  Metformin decreases growth of pancreatic cancer cells by decreasing reactive oxygen species: Role of NOX4. , 2015, Biochemical and biophysical research communications.

[16]  G. Melino,et al.  p63 supports aerobic respiration through hexokinase II , 2015, Proceedings of the National Academy of Sciences.

[17]  A. Zwinderman,et al.  Metformin in patients with advanced pancreatic cancer: a double-blind, randomised, placebo-controlled phase 2 trial. , 2015, The Lancet. Oncology.

[18]  A. Kimmelman,et al.  Metabolic Dependencies in RAS-Driven Cancers , 2015, Clinical Cancer Research.

[19]  N. Chandel.  Four key questions about metformin and cancer , 2014, BMC Biology.

[20]  S. Hess,et al.  The Basic Principles of FDG-PET/CT Imaging. , 2014, PET clinics.

[21]  W. Oyen,et al.  Glucose Metabolism in NSCLC Is Histology-Specific and Diverges the Prognostic Potential of 18FDG-PET for Adenocarcinoma and Squamous Cell Carcinoma , 2014, Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer.

[22]  P. Abbe,et al.  Metformin Blocks Melanoma Invasion and Metastasis Development in AMPK/p53-Dependent Manner , 2013, Molecular Cancer Therapeutics.

[23]  S. Lai,et al.  Effects of Metformin Versus Glipizide on Cardiovascular Outcomes in Patients With Type 2 Diabetes and Coronary Artery Disease , 2013, Diabetes Care.

[24]  N. Ohkohchi,et al.  Evaluation of serum high‐density lipoprotein cholesterol levels as a prognostic factor in gastric cancer patients , 2012, Journal of gastroenterology and hepatology.

[25]  M. Pollak.  Investigating metformin for cancer prevention and treatment: the end of the beginning. , 2012, Cancer discovery.

[26]  K. Ang,et al.  TP53 Disruptive Mutations Lead to Head and Neck Cancer Treatment Failure through Inhibition of Radiation-Induced Senescence , 2011, Clinical Cancer Research.

[27]  H. Sin,et al.  Total cholesterol, high density lipoprotein and triglyceride for cardiovascular disease in elderly patients treated with metformin , 2011, Archives of pharmacal research.

[28]  B. Viollet,et al.  Metformin inhibits hepatic gluconeogenesis in mice independently of the LKB1/AMPK pathway via a decrease in hepatic energy state. , 2010, The Journal of clinical investigation.

[29]  R. Karas,et al.  Baseline and on-treatment high-density lipoprotein cholesterol and the risk of cancer in randomized controlled trials of lipid-altering therapy. , 2010, Journal of the American College of Cardiology.

[30]  B. Viollet,et al.  Metformin, independent of AMPK, inhibits mTORC1 in a rag GTPase-dependent manner. , 2010, Cell metabolism.

[31]  C. Bertolotto,et al.  Targeting cancer cell metabolism: the combination of metformin and 2-deoxyglucose induces p53-dependent apoptosis in prostate cancer cells. , 2010, Cancer research.

[32]  A. Alavi,et al.  18F-FDG Uptake in Lung, Breast, and Colon Cancers: Molecular Biology Correlates and Disease Characterization* , 2009, Journal of Nuclear Medicine.

[33]  G. Eibl,et al.  Metformin disrupts crosstalk between G protein-coupled receptor and insulin receptor signaling systems and inhibits pancreatic cancer growth. , 2009, Cancer research.

[34]  P. Donnan,et al.  New Users of Metformin Are at Low Risk of Incident Cancer , 2009, Diabetes Care.

[35]  M. Pollak,et al.  Insulin and insulin-like growth factor signalling in neoplasia , 2008, Nature Reviews Cancer.

[36]  B. Viollet,et al.  Systemic treatment with the antidiabetic drug metformin selectively impairs p53-deficient tumor cell growth. , 2007, Cancer research.

[37]  R. DePinho,et al.  The Kinase LKB1 Mediates Glucose Homeostasis in Liver and Therapeutic Effects of Metformin , 2005, Science.

[38]  M. van Glabbeke,et al.  New guidelines to evaluate the response to treatment in solid tumors , 2000, Journal of the National Cancer Institute.